Luncheon Seminar

Jordi Mestres
（Chemotargets S.L.）
"Early Anticipation of Drug Safety Signals: from Off-Target Pharmacology Prediction to Machine Learning Models of Post-Marketing Data"

In the era of Artificial Intelligence, Machine Learning and Large Language Models, access to quality data has become of upmost importance. The increasing availability of large amounts of quality in vitro affinity data has promoted the development of state-of-the-art platforms for predictive off-target pharmacology, such as CLARITY®. With these tools, our ability to guide the design of novel active molecules for protein targets has increased dramatically. However, access to large amounts of quality safety data is still missing. In this talk, I will introduce our recent efforts in drug safety data collection and curation, how these quality safety data are made available for AI/ML modeling, and the impact for the early anticipation of adverse drug events at all stages of the drug discovery and development process.

The talk will review, with some use case examples, the quality safety data feeds that are currently being offered:

ClarityOne: one integrated Spontaneous Reporting System data feed with deduplicated reports, standardized terminology and COVID-corrected versions of VigiBase, FAERS, VAERS and JADER
ClaritySignals: the most comprehensive list of safety signals for drugs and drug clases but also for targets and target families extracted from disproportionate analyses of Spontaneous Reporting Systems but also from Congress Abstracts
ClarityStrata: pre-calculated subpopulation analyses of safety signals across some of the main patient parameters available in Spontaneous Reporting Systems (sex, age, weight and geography)

The session will finalize with a life demonstration of the new ClarityVista; product (formerly known as ClarityPV), the GUI interface and analytics platform to browse, search and analyze all safety data and signals in ClarityOne, ClaritySignals and ClarityStrata to assist its user to get a clear view of drug safety data, from off-target pharmacology to post-marketing signals.

 Takashi FUKUYAMA
（dotmatics K.K.）

Zsolt LEPP
（dotmatics K.K.）

Takahiro Inoue
（Elix, Inc.）

Kyohei Morimoto
（KAKEN PHARMACEUTICAL CO.,LTD）

Takahiro Inoue
（Elix, Inc.）

Sherry WINTER
（Elsevier B. V.）

Atsushi MIDORIKAWA
（WorldFusion Co,. Ltd.）
"Innovative Literature Analysis with LSKB and BERT (MNLI)"

Jimmy, Yen-Chu Lin
（Insilico Medicine ）
"Transforming Drug Discovery Through AI"

Jaokar Tulika
（Excelra）
"Harnessing the power of data to accelerate drug development"

Kai Kaburaki
（Patcore, Inc.）
"Introducing the Assay Request System (tentative name) ~Planned and efficient request for compound assay, with Design Hub~"